Hsa-miR-181a-5p, hsa-miR-182-5p, and hsa-miR-26a-5p as potential biomarkers for BCR-ABL1 among adult chronic myeloid leukemia treated with tyrosine kinase inhibitors at the molecular response

Hsa-miR-181a-5p, hsa-miR-182-5p, and hsa-miR-26a-5p as potential biomarkers for BCR-ABL1 among adult chronic myeloid leukemia treated with tyrosine kinase inhibitors at the molecular response

Abstract Background Tyrosine kinase inhibitors (TKIs) as first-line therapy for Chronic Myeloid Leukemia (CML) show a high success rate. However, a low number of patients with long-term treatment-free remission (TFR) were observed. Molecular relapse after imatinib discontinuation occurred at 50% at...

Full description

Bibliographic Details
Main Authors: Aliza Mohd Yacob, Nor Asiah Muhamad, Kian Meng Chang, Hamidah Akmal Hisham, Yuslina Mat Yusoff, Latifah Ibrahim
Format: Article
Language:English
Published: BMC 2022-03-01
Series:BMC Cancer
Subjects:
Hsa-miR-181a-5p
Hsa-miR-182-5p
Hsa-miR-26a-5p
Chronic myeloid leukemia
Tyrosine kinase inhibitors
Next generation sequencing
Online Access:https://doi.org/10.1186/s12885-022-09396-5

Internet

https://doi.org/10.1186/s12885-022-09396-5

Similar Items